PHARMACY

Dr. Reddy’s is selling the U.S. and select territory rights for Zembrace Symtouch and Tosymra to Upsher-Smith Labs for an upfront price of $70 million and $40.5 million in milestone and other considerations.

The FDA approval of biosimilar Herceptin provides an additional treatment option for patients across three types of cancer.

Teva's generic Albenza tablets are available in a dosage strength of 200 mg, in bottles of two tablets.

Ron Cerminaro is joining Camber as business and strategic project manager, sales operations.

Tilos Therapeutics develops products for the treatment of cancer, fibrosis and autoimmune diseases.

Jornay PM is the first and only ADHD stimulant medication that is dosed in the evening to improve and control symptoms throughout the day.

Nevada's electronic prescribing bill (AB 310), which was signed into law on June 7, will become effective Jan. 1, 2021.

Azurity Pharmaceuticals, formed by CutisPharma's acquisition of Silvergate, has 12 products serving multiple therapeutic areas.